Meeting
2020 Gastrointestinal Cancers Symposium
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).
Authors
Stacey Stein
Yale School of Medicine, New Haven, CT
Stacey Stein , Jeremy Snider , Margaret Elizabeth McCusker , Rebecca A. Miksad , Brian Michael Alexander , Emily Castellanos , Daniel Backenroth , Alexa Betzig Schrock , Russell Madison , Kenneth Robert Carson , Siraj Mahamed Ali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 310)
Abstract #
310
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Differential HER2 expression in resected gastric cancer: Is there prognostic value?
First Author: Sarah Fisher
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinicopathological features of HER2-low expressed advanced gastric cancers.
First Author: Izuma Nakayama
Poster
2021 ASCO Annual Meeting
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
First Author: Sun Young Rha
Poster
2019 Gastrointestinal Cancers Symposium
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari